Quantcast
Last updated on April 23, 2014 at 20:10 EDT

Latest Tyrosine kinase inhibitors Stories

2012-07-25 02:29:04

SUNNYVALE, Calif., July 25, 2012 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced the release of an updated Xpert(®) BCR-ABL Monitor test, now incorporating lot-specific standardization using the WHO (World Health Organization) BCR-ABL standards. The test is being released as a European CE-IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. The test, which runs on Cepheid's GeneXpert(®) System, detects the BCR-ABL mRNA transcript in the...

2012-07-22 22:20:44

WAYNE, N.J., SOUTH SAN FRANCISCO, Calif. and TOKYO, July 23, 2012 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), and Astellas Pharma Inc. (TSE: 4503) today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva(®) (erlotinib) tablets to Nexavar(®) (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone. The SEARCH (Sorafenib...

2012-07-02 22:03:20

Discovery may lead to new, more powerful precision medicines that thwart resistance to the common lung cancer drug Tarceva People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return–it's a question of when. And for far too many, it happens far too soon. Now, a team of researchers at the University of California, San Francisco's Helen Diller Family...

2012-06-17 22:22:09

AMSTERDAM and CAMBRIDGE, Massachusetts, June 18, 2012 /PRNewswire/ -- ~ Robust anti-leukemic activity in CML patients who have become resistant or intolerant to available tyrosine kinase inhibitors ~ 54% major cytogenetic response and 30% major molecular response reported in heavily pre-treated chronic-phase CML patients ~ Data supports ARIAD filing for EMA approval of ponatinib in Europe ARIAD...

2012-06-15 10:23:01

PARIS, June 15, 2012 /PRNewswire/ -- Results Presented at 17th Congress of the European Hematology Association Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec(R)...

2012-06-05 22:20:50

LAUSANNE, Switzerland, June 6, 2012 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent. The study was designed to determine the...

2012-06-04 02:25:40

LUX-Lung 3 trial results highlighted at the official ASCO Press Conference: Afatinib* delays lung cancer progression compared to standard chemotherapy BURLINGTON, ON, June 4, 2012 /CNW/ - The LUX-Lung 3 Phase III results showed that lung cancer patients taking the novel compound afatinib*, an irreversible ErbB Family Blocker, as a first-line treatment, lived for almost one year before their disease progressed (progression-free survival (PFS) of 11.1 months) versus just over half a...

2012-06-04 04:24:11

(Ivanhoe Newswire) --Almost twelve million -- that´s how many cancer patients are living in the U.S. But what happens when the patients are no longer responsive to the drugs created to treat them? It´s a problem researchers at Case Western Reserve University are working to better understand. Researchers say overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. They found many patients have developed resistance to the drug...

New Cancer Drug Targets Tumor Cells, Reduces Side Effects
2012-06-04 02:57:24

A clinical trial of an experimental new breast cancer treatment found that it extended the life expectancy of patients without the symptoms of the disease worsening, various media outlets reported on Sunday. The drug, TDM-1, is manufactured by Roche, and according to Naomi Kresge and Robert Langreth of Bloomberg, it works by carrying chemotherapy directly into cancer cells while successfully avoiding healthy ones, resulting in fewer side effects than conventional treatments. According...

2012-06-03 18:20:47

SOUTH SAN FRANCISCO, Calif., June 4, 2012 /PRNewswire/ -- Onyx Pharmaceuticals (Nasdaq: ONXX) today announced data from the Phase 3 GRID (GIST - Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib. The GRID study met its primary endpoint of progression-free survival (PFS)...